Condition
X-ALD
Total Trials
5
Recruiting
1
Active
1
Completed
1
Success Rate
33.3%-53% vs avg
Key Insights
Highlights
Success Rate
33% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
Termination Rate
40.0%
2 terminated out of 5 trials
Success Rate
33.3%
-53.2% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results33% success
Data Visualizations
Phase Distribution
1Total
P 1 (1)
Trial Status
Terminated2
Completed1
Withdrawn1
Recruiting1
Trial Success Rate
33.3%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT02699190Completed
LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
NCT05394064Phase 1Terminated
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
NCT05008874Terminated
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
NCT03047369Recruiting
The Myelin Disorders Biorepository Project
NCT03649919Withdrawn
Multi-center Clinical Study on the Diagnosis and Treatment Management of Rare Neurological Disease in Children
Showing all 5 trials